Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ ESTHER trial in Cameroon

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 29-37

  Meresse, Mégane ^a,b,c   Carrieri, Maria Patrizia ^a,b,c   Laurent, Christian ^d   Kouanfack, Charles ^e   Protopopescu, Camelia ^a,b,c   Blanche, Jérǒme ^a,b,c   Cohen, Julien ^a,b,c   Laborde Balen, Gabrièle ^f   Aghokeng, Avelin F ^d,g   Spire, Bruno ^a,b,c   Moatti, Jean Paul ^a,b,c   Delaporte, Eric ^d   Boyer, Sylvie ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e Hopital Central de Yaounde   (Cameroon)

^f French Ministry of Foreign Affairs   (Cameroon)

^g Institut de Recherche pour le Developpement Cameroon   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CLINICAL INDICATOR; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; PATIENT ATTITUDE; PATIENT CODING; PRIORITY JOURNAL; RISK ASSESSMENT; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VIROLOGICAL FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CAMEROON; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874441416     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2535     Document Type: Article

References (39)

1. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
2. Hull MW, Montaner J. Antiretroviral therapy: A key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep 2011; 8:85-93.
3. Eyer-Silva WA, Couto-Fernandez JC, Silva-de-Jesus C, Morgado MG. Prevalence of HIV type 1 drug resistance mutations in treatment-naive and experienced patients from resource-limited settings with universal access to antiretroviral therapy: A survey in two small Brazilian cities. Mem Inst Oswaldo Cruz 2008; 103:143-149.
4. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13:1099-1107.
5. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S112-S117.
6. El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa-a prospective cohort study. BMC Public Health 2011; 11:88.
7. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009; 38:746-756.
8. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antivir Ther 2003; 8:585-594.
9. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
10. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): A randomised non-inferiority trial. Lancet Infect Dis 2011; 11:825-833.
11. Boyer S, Eboko F, Camara M, et al. Scaling up access to antiretroviral treatment for HIV infection: The impact of decentralization of healthcare delivery in Cameroon. AIDS 2010; 24 Suppl 1:S5-S15.
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006 Revision. Geneva: World Health Organization 2006.
13. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001; 28:232-239.
14. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
15. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: Wiley; 2000.
16. Heckman J. The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Annals of Economic and Social Measurement 1976; 5:475-492.
17. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: Concepts and analytical approaches. Annu Rev Public Health 2000; 21:121-145.
18. Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006; 41:477-485.
19. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
20. Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: Five-year follow up of an observational cohort. PLoS ONE 2010; 5:e10460.
21. Fielding KL, Charalambous S, Stenson AL, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study. BMC Infect Dis 2008; 8:93.
22. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:769-773.
23. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55:460-465.
24. Bangsberg DR, Acosta EP, Gupta R, et al. Adherenceresistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
25. Gardner EM, Hullsiek KH, Telzak EE, et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010; 24:395-403.
26. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. Geneva: World Health Organization 2003.
27. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012; 13:406-415.
28. Mave V, Gahunia M, Frontini M, Clark R, Mushatt D. Gender differences in HIV drug resistance mutations and virological outcome. J Womens Health (Larchmt) 2011; 20:117-122.
29. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS ONE 2011; 6:e21795.
30. Wouters E, Van Damme W, Van Loon F, van Rensburg D, Meulemans H. Public-sector ART in the Free State Province, South Africa: Community support as an important determinant of outcome. Soc Sci Med 2009; 69:1177-1185.
31. Zachariah R, Teck R, Buhendwa L, et al. How can the community contribute in the fight against HIV/AIDS and tuberculosis? An example from a rural district in Malawi. Trans R Soc Trop Med Hyg 2006; 100:167-175.
32. Gusdal AK, Obua C, Andualem T, et al. Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda. AIDS Care 2011; 23:657-662.
33. Wouters E, van Loon F, van Rensburg D, Meulemans H. Community support and disclosure of HIV serostatus to family members by public-sector antiretroviral treatment patients in the Free State Province of South Africa. AIDS Patient Care STDS 2009; 23:357-364.
34. Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up: Contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007; 97:853-857.
35. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 2010; 15 Suppl 1:48-54.
36. Boyer S, Clerc I, Bonono CR, et al. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. Soc Sci Med 2011; 72:1383-1392.
37. Carrieri P, Marcellin F, Spire B. [Methods to assess adherence to antiretroviral treatment]. Developpement et Santé 2007; 187. French. (Accessed 12 November 2007.) Available from http://devsante.org/base- documentaire/medecine/methodes-pour-apprecier-lobservance-dutraitement- antiretroviral
38. Chalker JC, Andualem T, Gitau LN, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators. BMC Health Serv Res 2010; 10:43.
39. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 Suppl 2:S143-S151.